News for Royalty Pharma plc (RPRX)

For the second quarter, the S&P 500 gained 10.9%, the Nasdaq 18.0% and the Dow 5.5%. Opportunity Equity Strategy rose 15.3% net of fees. Read more here.

Morgan Stanley, a leading global financial services firm, has updated its outlook on Royalty Pharma (RPRX). The recent analyst rating, published on July 10, 202

Morgan Stanley analyst Terence Flynn has increased the price target for Royalty Pharma (RPRX) from $51 to $54, maintaining an Overweight rating on the stock. De

July is observed as Sarcoma Awareness Month. Sarcoma is a rare type of cancer that affects muscles, fat, nerves, and other connective tissues. As we get ready to welcome July, it's also time to track the important FDA decisions lined up for the month.

In the current market session, Royalty Pharma Inc. RPRX stock price is at $34.26, after a 1.72% drop. However, over the past month, the company's stock went up ...

**media[646117]**

PR NewswireNEW YORK, June 2, 2025 NEW YORK, June 2, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeli

PR NewswireDUBLIN, June 2, 2025 Definitive agreement to result in one-time $225 million cash payment Theravance Biopharma retains rights to up to $150 mill

Theravance Biopharma, Inc. (TBPH), Monday announced an agreement to sell remaining interest in net sales of Trelegy Ellipta, a chronic obstructive pulmonary disease or asthma treatment, to GSK (GSK) for $225 million in cash.

**media[628751]**

Morgan Stanley has resumed its coverage of Royalty Pharma (RPRX), assigning it an Overweight rating and setting a price target of $51. The financial institution

Received overwhelming shareholder approval with 99.9% of votes cast in favorSimplified structure benefits shareholders through strengthened shareholder alignmen

Royalty Pharma reported 12% growth in Q1 royalty receipts, driven by Vertex, GSK, and Roche. Read why RPRX stock is a Buy.

PR NewswireDUBLIN, May 8, 2025 YUPELRI® (revefenacin) net sales of $58.3 million, recognized by Viatris, increased 6% versus Q1 20241 TRELEGY net sales of

**media[618818]**

PR NewswireCAMBRIDGE, Mass., May 1, 2025 -- Achieved 61% year-over-year growth with $149.4 million in AYVAKIT net product revenues in the first quarter 202

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (”œPureTech” or the ”œCompany”) today announces its results for the year ended December 31, 2024, as well a

Royalty Pharma PLC (RPRX) has announced its participation in a fireside chat at TD Cowen's 45th Annual Health Care Conference, scheduled for March 4, 2025, at 2

**media[552855]**